• Taihangia rupestris: Wild vs Cultivated Bioactivity

  2026-08-20

  A 2026 RSC Advances study integrates UPLC-MS/MS, complementary antioxidant assays, α-glucosidase inhibition, activity-guided screening, and molecular docking to compare wild and cultivated Taihangia rupestris leaves. Foothill cultivation produced the strongest chemical and functional profile, supporting sustainable cultivation while showing why DPPH results should be interpreted alongside orthogonal biochemical measurements.

• Dye Models for Small Biopsies: Study Findings

  2026-08-20

  A 2023 study evaluated five dyes as pre-processing markers for small biopsy fragments and found that merbromin, hematoxylin, and Alcian blue improved tissue visibility during laboratory handling. Hematoxylin was favored for routine use because it combined improved observability with lower toxicity and no reported interference during standard slide examination.

• Cycloheximide for Protein Turnover and Apoptosis

  2026-08-19

  Cycloheximide is a practical protein biosynthesis inhibitor for separating newly synthesized proteins from pre-existing pools in apoptosis, inflammasome, and protein stability experiments. Its strongest advantage is experimental timing: short treatment and washout designs can expose protein turnover and translational dependencies that endpoint assays miss.

• ALA-PDT, Ferroptosis, and HPV Immunity

  2026-08-19

  A 2026 study identifies macrophage ferroptosis as an immune-regulatory mechanism of 5-aminolevulinic acid photodynamic therapy in HPV-associated disease. Its data connect the STEAP3/p53/SLC7A11 pathway with M1 polarization and show that treated macrophage-conditioned medium suppresses HPV16-positive SiHa cell activity and migration.

• Puromycin dihydrochloride: Protocol & QC Guide

  2026-08-18

  Puromycin dihydrochloride is an aminonucleoside antibiotic used to select pac-expressing cells and to create controlled protein synthesis or ribosome-focused assays. Its broad cell-type response and irreversible cytotoxic effect require an empirical kill curve, appropriate vehicle controls, and careful separation of selection, translation, and autophagy-related endpoints.

• BKT140: Designing CXCR4 Functional Assays

  2026-08-18

  BKT140 and BL-8040 provide a practical route to interrogate CXCR4 biology across cancer-cell migration, survival, and stem-cell trafficking. This guide translates receptor mechanism into assay-selection, controls, formulation, and interpretation decisions.

• CAFs, Lactylation, and Oxaliplatin Resistance in CRC

  2026-08-17

  A 2025 Cancer Letters study links glycolytic cancer-associated fibroblasts to oxaliplatin resistance in colorectal cancer through a lactate–ANTXR1 lactylation pathway. Its experimental framework suggests that disrupting stromal lactate transfer may reduce cancer stemness and improve chemotherapy response, although clinical validation remains necessary.

• Caspase-3 Colorimetric Assay Kit Workflow

  2026-08-17

  Turn apoptosis biology into a practical, quantitative workflow with rapid DEVD-dependent caspase-3 activity detection. This guide connects the assay to macrophage stress research, disease modeling, experimental controls, and troubleshooting strategies for more reliable caspase activity measurement.

• Acetoacetic acid sodium salt for Metabolic Assays

  2026-08-16

  Acetoacetic acid sodium salt enables controlled ketone-body supplementation, calibration, and stress-testing workflows in energy metabolism research. This guide combines practical formulation advice with analytical controls for diabetes metabolic imbalance and diabetic ketoacidosis study models.

• EZ Cap™ EPO mRNA: From Design to Assay

  2026-08-15

  EZ Cap™ EPO mRNA supports controlled human erythropoietin mRNA expression in mammalian research. This article connects Cap 1 and ψUTP engineering with assay controls, delivery decisions, and lessons from targeted spinal cord injury research.

• 2X HyperFusion High-Fidelity Master Mix for CRISPR PCR

  2026-08-14

  Use 2X HyperFusion High-Fidelity Master Mix to generate accurate, blunt-ended amplicons for cloning, CRISPR genotyping, and sequencing-ready workflows. This practical guide connects the mix’s proofreading performance with assay choices inspired by a bufalin–CRISPR/Cas9 nanomedicine study.

• Wortmannin: Reading PI3K Signals with Control

  2026-08-14

  Wortmannin is a PI3K inhibitor that can reveal whether lipid-kinase activity is functionally upstream of cellular entry, survival, or apoptosis. This guide connects mechanistic pharmacology with assay design, using a reovirus entry study to define controls, limitations, and translational relevance.

• Enhanced ECL for Microglial Mechanisms

  2026-08-13

  How sensitive HRP-based western blot chemiluminescence detection can strengthen mechanistic and translational interpretation of ectomesenchymal stem cell therapy in intracerebral hemorrhage.

• Lactate–H3K18la Axis Drives HCC Immune Resistance

  2026-08-13

  This 2026 hepatocellular carcinoma study identifies a lactate-induced H3K18la–KIF20A–c-Myc–PD-L1 pathway that connects glycolytic metabolism with immune checkpoint resistance. Its clinical, molecular, cellular, and xenograft data suggest that glycolysis inhibition may help restore anti-PD-1 activity, although validation in more representative models remains necessary.

• 2-APB and the ER Calcium Cell-Fate Switch

  2026-08-12

  2-APB provides a practical way to interrogate how ER calcium release, calpain activity, autophagy, and apoptosis intersect under metabolic stress. This thought-leadership guide translates findings from Bombyx mori into a rigorous framework for calcium signaling, SOCE, oxidative injury, and preclinical model development.

8041 records 2/537 page Previous Next 12345 下5页 Last page